Press Releases

Roswell Park Comprehensive Cancer Center and the Roswell Park Alliance Foundation are celebrating the 20th anniversary of the Herd About Buffalo public art program with a commemorative auction.

New research from a team at Roswell Park suggests that a drug widely prescribed to control blood pressure may improve patients’ response to cancer immunotherapy.

Nurses, physician assistants and nurse practitioners are an integral piece of Roswell Park Comprehensive Cancer Center’s mission. Day in and day out, they are central to the multidisciplinary and integrative approach that drives the care of each and every Roswell Park patient. Drs. Andrew Storer and Karen Sharrah have been newly appointed to critical leadership roles that will guide further growth in for this team of dedicated professionals.

Research led by a team from Roswell Park details a promising new strategy for overcoming immunotherapy treatment resistance by zeroing in on dendritic cells and enhancing their function as “accessory cells” supporting other immune cells.

Giving patients with relapsed or refractory mantle cell lymphoma (MCL) access to more treatment options, Roswell Park Comprehensive Cancer Center has been approved to administer the FDA-approved chimeric antigen receptor (CAR) T-cell therapy Tecartus. The immunotherapy drug is manufactured by Kite, a subsidiary of Gilead Sciences.

Roswell Park Comprehensive Cancer Center’s Chief of Myeloma, Jens Hillengass, MD, is slated to speak at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Congress on Hematologic Malignancies, happening October 9 and 10.

Subhamoy Dasgupta, PhD, established his own research laboratory in 2017 when he came to Roswell Park Comprehensive Cancer Center fresh from a postdoctoral research fellowship in Texas. Now he has received an NIH Director’s New Innovator Award for 2020.

A toddler from Niagara Falls, NY, will celebrate her 2nd birthday this month after successfully undergoing CAR T immunotherapy and stem cell transplant through the Roswell Park Oishei Children’s Cancer and Blood Disorders Program to treat the leukemia she was diagnosed with at only 5 weeks old.

Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, will receive a C-Level Executive Award for 2020 from the media outlet Buffalo Business First.